Heally

1. 3. Current product pages say there is no required subscription and payment is due only when a refill is ordered; the general FAQ still describes automatically scheduled refills until cancellation. Confirm which arrangement applies. The FAQ also describes a card authorization about 48 hours before an appointment and charge only after approval. A universal cancellation deadline, refund rule or charge amount is not established. https://getheally.com/patients/faq
2. 4. Wegovy and Ozempic are separately named injection programs. Their prices are distinct starting advertisements, not interchangeable guarantees. Current text explicitly describes injection pens. https://getheally.com/patients/semaglutide https://getheally.com/patients/ozempic
3. 5. The current offer explicitly names the Wegovy pill and its 1.5 mg starter dose. The prior unqualified oral classification is refined to brand semaglutide, not evidence of a sold-formulation change. Rybelsus is separately offered for diabetes from $199/month; its lack of a weight-loss indication is not a reason to erase it from this treatment catalog. https://getheally.com/patients/wegovy-pills https://getheally.com/patients/rybelsus
4. 6. Zepbound and Mounjaro are separate named tirzepatide offers. The page describes a single-dose injection pen; form and dose still affect the final price. A navigation promotion calls the $299 figure a new-patient offer, without establishing the later renewal rate. https://getheally.com/patients/tirzepatide https://getheally.com/patients/mounjaro
5. 7. The page explicitly offers clinician evaluation for Saxenda, Victoza or compounded liraglutide and describes daily injections. It does not establish the exact dispensed device. https://getheally.com/patients/liraglutide
6. 8. A $199/month starting figure appears for the overall liraglutide program, while another section says medication is billed separately. No formulation-specific medication invoice or allocation to Saxenda, Victoza or compounded treatment is established; the figure is not assigned to either record. https://getheally.com/patients/liraglutide

September 2026

1. 9. Rybelsus (oral brand semaglutide) is also sold but the page explicitly states it 'is not FDA approved for weight loss,' so it is excluded from these entries. The $149/month oral figure is described as the 'semaglutide pill' price; it is unclear from the text whether this is the brand Wegovy pill (approved Dec 2025, also discussed on the page) or a general oral program, so it is recorded generically as oral semaglutide.